Skip to main content

Biotech Superstar Dies

Alejandro Zaffaroni, who launched companies that developed birth control pills, microarrays, and transdermal drug patches, has died at age 91.  

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

ZAFFARONI FOUNDATIONA successful biotech entrepreneur whose companies pioneered the technology behind transdermal patches, DNA chips, and the birth control pill, died at his home in California at the age of 91. Alejandro Zaffaroni was the man behind Alza, Affymetrix, Affymax, and many other successful firms. “He always started with a big idea behind his companies and then adapted on the ground to the reality of what could be achieved,” Isaac Stein, a business partner of Zaffaroni, told The New York Times.

According to the Times, Zaffaroni was born in Uruguay and became an orphan at age 18. He came to the U.S. for his graduate work in biochemistry on corticosteroids. During the 1950s and '60s he became an accomplished scientist at Syntex Pharmaceuticals. Writing for The Scientist in 1988, David Moreau, the first managing director of Syntex in the U.K., described how Zaffaroni’s advances in paper chromatography of steroids contributed to the development of “fluocinolone acetonide (known worldwide as Synalar), the oral progestins that made the birth-control pill possible, non-virilizing androgens such as oxymetholone (still used for the treatment of aplastic anemia), paramethasone and many others.”

Zaffaroni’s business acumen and congenial nature helped him to lure successful academics to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris
Using TCR Repertoire Sequencing to Advance Immunology Research

Using TCR Repertoire Sequencing to Advance Immunology Research

Miltenyi
Mapping Clonal Mosaicism in Aging Tissues

Mapping Clonal Mosaicism in Aging Tissues

Mission bio

Products

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo
Conceptual image of ice and frost.

The VAULT100 PRO: Inside the most advanced Stirling Ultracold ULT freezer ever built.

Stirling Ultracold logo